TALOPH(SH:600222) Sou Hu Cai Jing·2025-12-30 14:39Core Viewpoint - Tai Long Pharmaceutical (600222) has announced the use of idle self-owned funds for entrusted wealth management, aiming to invest up to 250 million yuan in low-risk financial products to enhance returns while ensuring fund safety [1] Group 1: Stock Performance - As of December 30, 2025, Tai Long Pharmaceutical's stock closed at 6.66 yuan, up 1.52% from the previous trading day, with a total market capitalization of 3.822 billion yuan [1] - The stock opened at 6.55 yuan, reached a high of 6.77 yuan, and a low of 6.50 yuan, with a trading volume of 1.55 billion yuan and a turnover rate of 4.08% [1] Group 2: Wealth Management Announcement - The company held its sixth meeting of the tenth board of directors on December 30, 2025, where it approved the use of no more than 250 million yuan of idle self-owned funds for entrusted wealth management [1] - The investment will focus on low-risk financial products provided by listed financial institutions, including bank wealth management, money market funds, and reverse repos, with a single term not exceeding 6 months [1] - The wealth management period is set for within 12 months from the date of board approval, and the funds can be rolled over within the approved limit [1] - This matter does not require submission for shareholder meeting approval, and the company has established relevant risk control measures to ensure fund safety without affecting the normal operation of its main business [1]